scholarly journals Isolated Splenic Metastases of Her2+++ Gastroesophageal Junction Adenocarcinoma

2016 ◽  
Vol 9 (1) ◽  
pp. 154-157 ◽  
Author(s):  
Julie Sigrand ◽  
Camille Bazin ◽  
Jacques Ewald ◽  
Slimane Dermeche ◽  
Pauline Ries ◽  
...  
Keyword(s):  
Gastroesophageal Junction ◽  
Celiac Trunk ◽  
Survival Outcome ◽  
Term Survival ◽  
Gastroesophageal Junction Adenocarcinoma ◽  
Arch Pathol ◽  
Multiple Metastases ◽  
Splenic Metastases ◽  
Afferent Lymph

Isolated metastases from gastric adenocarcinoma to the spleen are very infrequent. Usually, there are multiple metastases from gastric cancer, and isolated splenic metastases are very rare [Lam and Tang: Arch Pathol Lab Med 2000;124:526-530] because of certain anatomical and physiological characteristics (e.g., angulation between the splenic artery and celiac trunk, paucity of afferent lymph flow toward the spleen, contractility of the spleen and major immune content). Here, we report 2 cases of isolated splenic metastases from an adenocarcinoma of the gastroesophageal junction, both with long-term survival outcome and overexpression of Her2.

scholarly journals Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab

2018 ◽  
Vol 12 (2) ◽  
pp. 532-539 ◽  
Author(s):  
Maria Angeles Gil-Delgado ◽  
Olivier Lucidarme ◽  
Jean Baptiste Bachet ◽  
Naima Mahi ◽  
David Khayat
Keyword(s):  
Liver Metastases ◽  
Metabolic Response ◽  
Controlled Trial ◽  
Gastroesophageal Junction ◽  
Complete Response ◽  
Term Survival ◽  
Long Term Survival ◽  
Gastroesophageal Junction Adenocarcinoma ◽  
Positron Emission

We report a case of long-term survival with complete response of liver metastases within RAINBOW, a randomized, controlled trial of ramucirumab 8 mg/kg intravenously (days 1, 15) versus placebo, both plus paclitaxel 80 mg/m2 intravenously (days 1, 8, 15), every 4 weeks in patients with previously treated advanced gastroesophageal junction adenocarcinoma. A 64-year-old man with gastroesophageal junction adenocarcinoma and liver metastases received first-line folinic acid, 5-fluorouracil plus oxaliplatin (FOLFOX) following jejunostomy. On liver progression, he enrolled in RAINBOW (April 2012), receiving ramucirumab. In November 2013, positron emission tomography scan was consistent with complete metabolic response, confirmed by a follow-up scan in March 2016.

An oncology clinical trial design with randomization adaptive to both short- and long-term responses

2017 ◽  
Vol 28 (7) ◽  
pp. 2015-2031 ◽  
Author(s):  
Hao Liu ◽  
Xiao Lin ◽  
Xuelin Huang
Keyword(s):  
Trial Design ◽  
Clinical Trial Design ◽  
Therapeutic Benefit ◽  
Survival Outcome ◽  
Operating Characteristics ◽  
Short Term ◽  
Term Survival ◽  
Long Term Survival ◽  
Term Response

In oncology clinical trials, both short-term response and long-term survival are important. We propose an urn-based adaptive randomization design to incorporate both of these two outcomes. While short-term response can update the randomization probability quickly to benefit the trial participants, long-term survival outcome can also change the randomization to favor the treatment arm with definitive therapeutic benefit. Using generalized Friedman’s urn, we derive an explicit formula for the limiting distribution of the number of subjects assigned to each arm. With prior or hypothetical knowledge on treatment effects, this formula can be used to guide the selection of parameters for the proposed design to achieve desirable patient number ratios between different treatment arms, and thus optimize the operating characteristics of the trial design. Simulation studies show that the proposed design successfully assign more patients to the treatment arms with either better short-term tumor response or long-term survival outcome or both.

Postoperative Morbidity in Curative Resection of Gastroesophageal Carcinoma Does Not Impact Long-term Survival

2015 ◽  
Vol 81 (12) ◽  
pp. 1228-1231
Author(s):  
Jennifer E. Samples ◽  
Anna C. Snavely ◽  
Michael O. Meyers
Keyword(s):  
Overall Survival ◽  
Lymph Node ◽  
Neoadjuvant Therapy ◽  
Postoperative Morbidity ◽  
Gastroesophageal Junction ◽  
Morbidity And Mortality ◽  
Term Survival ◽  
Long Term Survival ◽  
Nodal Dissection

Significant morbidity and mortality have historically been reported for surgical resection of gastric and gastroesophageal junction tumors. We evaluated our experience to determine morbidity and mortality and evaluated demographic and pathologic risk factors associated with postoperative outcome and long-term survival. A retrospective, Institutional Review Board-approved, single-institution database identified 102 patients who underwent resection with curative intent for gastroesophageal junction or gastric carcinoma from 2004 to 2012. The method of Kaplan and Meier was used to describe overall survival and estimate median survival. Of 102 patients, 74 were male and 28 were female. Of these, 24 patients were > 70 years of age at surgery (median = 62.9). Forty esophagectomies, 25 total gastrectomies, and 37 subtotal gastrectomies were performed. Two patients died (one esophagectomy and one gastrectomy). Forty-one developed a complication: 17 minor and 35 major, including six anastomotic leaks. Patients with low preoperative albumin ( P = 0.01) and increased age ( P = 0.05) were associated with having a postoperative complication; extent of nodal dissection ( P = 0.48), jejunostomy (0.24), performance status ( P = 0.77), type of surgery ( P = 0.74), and neoadjuvant therapy ( P = 0.24) were not associated. More extensive nodal dissection was associated with a decreased risk of death ( P = 0.007). Having any complication ( P = 0.20), an anastomotic leak ( P = 0.17), worse grade of complication ( P = 0.15), presence of feeding jejunostomy tube ( P = 0.17), and neoadjuvant therapy ( P = 0.30) were not associated with changes in overall survival. Thorough lymph node dissection improves survival without increasing postoperative morbidity. The data advocate for increased lymph node yield and close attention to nutritional support in gastroesophageal carcinoma patients.

Long-term survival outcome following Staphylococcus aureus bacteraemia

2013 ◽  
Vol 18 (3) ◽  
pp. 102-109 ◽  
Author(s):  
Chong W. Ong ◽  
Jan L. Roberts ◽  
Peter J. Collignon
Keyword(s):  
Staphylococcus Aureus ◽  
Survival Outcome ◽  
Term Survival ◽  
Long Term Survival

scholarly journals Gastric Mucinous Cancer Histology: Clinicopathological Characteristics and Prognostic Value

2016 ◽  
Vol 2016 ◽  
pp. 1-9
Author(s):  
Chen Jian-Hui ◽  
Cai Shi-Rong ◽  
Wu Hui ◽  
Xu Jian-bo ◽  
Wu Kai-Ming ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Prognostic Value ◽  
Clinicopathological Characteristics ◽  
Survival Outcome ◽  
Clinicopathological Features ◽  
Histological Type ◽  
Biological Behavior ◽  
Term Survival ◽  
Long Term Survival

MC tended toward worse tumor biological behavior and long-term survival outcome compared to WMDC. Moreover, MC also showed worse clinicopathological features and survival outcome in some selected patients. For these reasons, MC should be deemed as a special histological type of gastric cancer with worse clinicopathological features and survival outcome.

LONG TERM SURVIVAL OUTCOME FOLLOWING RADICAL CYSTECTOMY FOR TCC OF THE BLADDER - COMPARISON BETWEEN PRIMARY AND SALVAGE RADICAL CYSTECTOMY

2009 ◽  
Vol 181 (4) ◽  
pp. 633 ◽  
Author(s):  
Sanjai K Addla ◽  
Purushotham Naidu ◽  
Satish B Maddineni ◽  
Noel W Clarke ◽  
Vijay AC Ramani
Keyword(s):  
Radical Cystectomy ◽  
Survival Outcome ◽  
Term Survival ◽  
Long Term Survival
Sign in / Sign up

Export Citation Format

Share Document